Immunic Stock Set to Reverse Split on Monday, April 27th (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) shares are going to reverse split on the morning of Monday, April 27th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, April 26th.

Immunic Stock Performance

Shares of Immunic stock traded down $0.07 during trading on Wednesday, reaching $1.11. The company’s stock had a trading volume of 3,530,615 shares, compared to its average volume of 1,828,895. The stock has a 50-day moving average price of $1.06 and a two-hundred day moving average price of $0.83. Immunic has a one year low of $0.51 and a one year high of $1.51.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). On average, research analysts anticipate that Immunic will post -0.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on IMUX. D. Boral Capital lowered Immunic from a “buy” rating to a “hold” rating in a research report on Wednesday. upgraded Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. HC Wainwright decreased their price objective on Immunic from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, March 2nd. Guggenheim began coverage on Immunic in a research report on Tuesday, March 24th. They issued a “buy” rating and a $7.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $6.17.

Institutional Investors Weigh In On Immunic

Several large investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC acquired a new stake in shares of Immunic in the 4th quarter valued at approximately $2,337,000. Vanguard Group Inc. boosted its holdings in shares of Immunic by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after buying an additional 219,957 shares during the last quarter. Laurion Capital Management LP boosted its holdings in shares of Immunic by 106.3% in the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after buying an additional 2,000,000 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Immunic by 544.6% in the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after buying an additional 2,888,829 shares during the last quarter. Finally, Focus Partners Wealth boosted its holdings in shares of Immunic by 1.5% in the 3rd quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock valued at $2,276,000 after buying an additional 39,063 shares during the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.